Performance Highlights Quarter ended 30th June 2025 P O W E R F I N A N C E C O R P O R A T I O N L T D . A M a h a r a t n a P S U Funding for a brighter Tomorrow Table of Contents PFC AT A GLANCE Powering Nation's Development CONSOLIDATED PERFORMANCE III. IV. STANDLAONE PERFORMANCE ESG AT PFC Page • 2 I. II. PFC Group structure PFC Financing Progress Consolidated highlights Key Consolidated Financials Highlights Earning Update Asset quality Operational Performance Shareholder Outlook ESG Vision ESG journe ...

Financial Performance & Strategic Aspirations - Novo Nordisk achieved sales growth of 18% (CER) in the first six months of 2025, with operating profit growth of 29% (CER)[11] - Obesity care sales reached DKK 38.8 billion, a 58% increase at CER, highlighting the strong performance in this therapeutic area[11] - Rare disease sales increased by 15% at CER, reaching DKK 9.5 billion[11] - The company returned DKK 36.5 billion to shareholders, demonstrating a commitment to attractive capital allocation[11] Market Dynamics & Key Products - In the US, the branded anti-obesity medication market experienced growth exceeding 160%[28] - International Operations saw sales growth of 19%, driven by GLP-1 Diabetes and Obesity care[33] - Total GLP-1 class market share in International Operations reached 71%[36] - Global diabetes and obesity unmet need is significant, with less than 1% of people with obesity globally treated with branded AOMs[44] Research & Development Highlights - Amycretin is advancing to phase 3 development based on successful phase 1b/2a trial results, showing significant body weight loss[49, 53] - Semaglutide 2.4 mg demonstrated a 20% reduction in MACE in the SELECT trial for people with overweight or obesity and established CVD[249]

Clinical Programs & Pipeline - Entrada Therapeutics expects to have four active clinical-stage programs by the end of 2025[7, 17] - ENTR-601-44 is currently dosing patients in the UK and EU and is authorized in the US[7] Data from Cohort 1 of the ELEVATE-44-201 study is expected in the first half of 2026[3, 38] - ENTR-601-45 patient study is currently enrolling in the UK and EU, with first patient dosing expected in Q3 2025 and initial data from the first patient cohort expected in mid-2026[3, 7, 41] - Global regulatory filings for ENTR-601-50 are on track for submission in Q4 2025, and for ENTR-601-51 in 2026[3, 7, 42] - Vertex's DM1 program, VX-670, has an ongoing MAD portion of its global Phase 1/2 study to evaluate safety and efficacy, with completion of enrollment and dosing expected in H1 2026[7, 18] Financial Position - The company reports a cash balance of approximately $354 million as of June 30, 2025[8] - This cash balance is expected to provide a runway into Q2 2027[3, 8, 60] EEV Platform & Technology - The company's Endosomal Escape Vehicle (EEV) technology achieves approximately 50% endosomal escape, compared to a standard of approximately 2%[12] - EEV therapies demonstrate approximately 90% cellular uptake[13] ENTR-601-44 Phase 1 Data - The ENTR-601-44-101 study showed strong clinical safety up to 6 mg/kg, with no treatment-related adverse events reported[21, 22] - Favorable target exposure and engagement were observed at 6 mg/kg, with statistically significant exon skipping versus placebo[30, 33]

A Progressive Montney Producer for the New Energy Market Investor Presentation August 2025 Cautionary Statements / Advisory This presentation contains forward-looking information and specified financial measures such as non-GAAP financial measures, non-GAAP ratios, capital management measures and supplementary financial measures. Readers are advised to read this presentation in conjunction with the advisories contained at the end of this presentation (see "Advisories") and the footnotes contained on page 35 ...

Financial Performance - Q2 2025 - Revenue from Operations reached ₹4401 billion, a 17% increase compared to Q1 2025 and an 8% increase compared to Q2 2024[7] - Adjusted EBITDA was ₹617 billion, showing a 42% increase compared to Q1 2025 and a 26% increase compared to Q2 2024[7] - Adjusted Net Profit After Tax was ₹050 billion[7] - The company's liquidity stands at US$339 million, including a cash balance of US$191 million and undrawn loan facilities of US$148 million[7] Segment Performance - Q2 2025 vs Q1 2025 - **Carbon:** Revenue increased by 17% to ₹319 billion, with Adjusted EBITDA increasing by 26% to ₹52 billion Sales volumes increased by 11% to 664 MT[12,8] - **Advanced Materials:** Revenue increased by 13% to ₹82 billion, with Adjusted EBITDA increasing significantly by 317% to ₹08 billion Sales volumes increased by 17% to 70 MT[13] - **Cement:** Revenue increased by 13% to ₹33 billion, with Adjusted EBITDA increasing significantly by 315% to ₹02 billion Sales volumes increased by 01% to 699 MT[14,11] Debt and Cash Flow - Total Capex for the six months period was US$28 million[7] - Net operating cash outflows include a net working capital increase of ₹1195 billion, compared to inflows of ₹143 billion in H1 2024[37,41] - Gross Term Debt is US$834 million as of June 2025[37]

Operational Highlights - South Bow's pipeline footprint spans 4,900 km[2] - The company safely and reliably delivers 1.25 million barrels of crude oil per day (MMbbl/d)[2] - Terminal storage capacity reaches 7.6 million barrels (MMbbl)[2] - Keystone Pipeline throughput commitments are currently at 585 Mbbl/d[9] Financial Highlights - The company has 208 million shares outstanding[3] - Market capitalization stands at $5.5 billion[3] - Enterprise value is $10.9 billion[3] - The annual base dividend is $2.00 per share, resulting in a dividend yield of approximately 8%[3] - Q2 2025 normalized EBITDA was $250 million[5] - The net debt-to-normalized EBITDA ratio is 4.6x[5] - The company anticipates exiting 2025 with a net debt-to-normalized EBITDA ratio of approximately 4.8x[7] Contractual Framework - Approximately 90% of normalized EBITDA is contracted[13] - 96% of revenue exposure is to investment-grade counterparties[13] - Approximately 95% of customers are refiners, vertically integrated companies, and producers[13]

Company Overview - Enerflex's market capitalization is CAD$1.4 billion with an annual dividend of CAD$0.15 per share, resulting in a dividend yield of 1.3%[3] - The company has been operating for 45 years and employs approximately 4,400 people across 7 core countries, with 25 BOOM projects[3] Market Position and Growth - Global demand for natural gas is forecasted to grow by 15% over the next decade, requiring U S and Canadian supply to increase by approximately 25%[15] - Approximately 20 Bcf/d is expected to be added to North American LNG export capacity by 2030, more than doubling the existing capacity of 14 Bcf/d[22] - Data center power demand is projected to reach approximately 700 Twh by 2035, potentially creating a demand of approximately 5 0 Bcf/d[24, 25] Financial Performance and Strategy - Adjusted gross margin from recurring sources accounts for 65% of the total[27] - The company's bank-adjusted net debt-to-EBITDA ratio is 1 3x, compared to a peer range of 3 0x to 4 6x for contract compression and energy infrastructure peers[33] - Enerflex has repaid $396 million of long-term debt since the beginning of 2023, reducing the leverage ratio from 3 3x at year-end 2022 to 1 3x by Q2/25[39, 42] - The company is authorized to acquire up to approximately 6 2 million common shares through March 31, 2026, representing 5% of the float[44, 76] Energy Infrastructure Business - The company's Energy Infrastructure business has approximately $1 3 billion in revenue under contract, with a weighted average contract term of approximately 5 years, extending to 2033[54] - Enerflex operates approximately 1 1 million horsepower of compression internationally, including 23 BOOM gas plants and 2 BOOM produced water treatment facilities[54] - Approximately 75% of the U S contract compression fleet operates in the Permian Basin, with over 20% of the total fleet being electric drive, and fleet utilization exceeding 90% over the past two years[58]

Financial Performance - Net income available to common stockholders for the three months ended June 30, 2025, was $92877 thousand, or $0.90 per share[58, 60] - Funds from Operations (FFO) for the three months ended June 30, 2025, was $66335 thousand, or $0.64 per share[60] - Adjusted Funds from Operations (AFFO) for the three months ended June 30, 2025, was $51888 thousand[60] - Cash Same Store NOI growth for Q2 2025 was 7.3%[16, 18] - Rental revenues and tenant expense reimbursements for the three months ended June 30, 2025, were $112234 thousand[58, 60] Investment and Capital Activities - Q2 2025 acquisitions totaled $123.5 million[21] - Acquisitions under contract as of August 5, 2025, totaled $472.5 million[21] - Q2 2025 dispositions totaled $114.5 million[21] - Year-to-date through June 30, 2025, the company issued 3506371 shares of common stock, receiving gross proceeds of $237.4 million[25] Portfolio Overview - Portfolio occupancy as of June 30, 2025, was 97.7%[29] - The portfolio consists of approximately 18.9 million square feet and 47 improved land parcels consisting of approximately 150.6 acres as of June 30, 2025[29]

Financial Performance - Q2 2025 - Total Revenue was €747 million[19, 21], a decrease of 0.8% year-over-year[21] - Organic revenue declined by 1.1%[9, 19, 21] due to a 1% volume decline[9] - Adjusted Gross Margin contracted by 310 bps year-over-year to 27.8%[9, 19, 21] - Adjusted EBITDA decreased by 7% year-over-year to €129 million[9, 19, 21] - Adjusted EPS decreased by 9% year-over-year to €0.40[9, 19, 21] Cash Flow - YTD 2025 (6 Months Ended June 30) - Adjusted Free Cash Flow was €49 million[22] - Adjusted Free Cash Flow as a percentage of adjusted profit for the period was 43%[22] compared to 32% in the same period last year[22] Outlook - 2025 Guidance - Organic Revenue growth is expected to be between 0% and -2%[25] - Adjusted EBITDA is expected to decline by 3% to 7% year-over-year[25] - Adjusted EPS is projected to be in the range of €1.64 to €1.76[25] - Adjusted Free Cash Flow Conversion is expected to be 90%+[25]

Financial Performance & Outlook - The company delivered 12% comparable EBITDA growth in Q2 2025 compared to Q2 2024[15] - The company is increasing its 2025E comparable EBITDA outlook to $108 billion - $110 billion[15] - The company is targeting a long-term debt-to-EBITDA ratio of 475x[15] - The company's Q2 2025 comparable EBITDA from continuing operations was $2625 million, compared to $2348 million in Q2 2024[32] - Canadian Natural Gas Pipelines saw a 3% increase in net income in Q2 2025 compared to Q2 2024[32] - Power and Energy Solutions experienced a 33% increase in comparable EBITDA in Q2 2025 compared to Q2 2024[32] Growth Projects & Capital Allocation - Approximately 70% of the ~$85 billion of assets are expected to be placed into service in 2025, tracking ~15% under budget[15] - The company sanctioned ~$45 billion of high-value capital projects over the past nine months[25] - Growth projects sanctioned in 2025 YTD have a weighted average unlevered after-tax IRR of ~120%[23] Sustainability - The company reduced absolute methane emissions by 12% between 2019 and 2024 while increasing throughput by 15% and natural gas comparable EBITDA by 40%[39] - The company introduced a methane intensity reduction target of 40-55% by 2035 from 2019 levels[39]